An update review on HPV testing methods for cervical neoplasia

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 2, 2009, Pages 123-131

  Koliopoulos, George ^a   Valasoulis, George ^b   Zilakou, Evgenia ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b NONE

Author keywords

Cervical cancer; Cervical screening; Cervix uteri; HPV testing; HPV typing

Indexed keywords

MESSENGER RNA; VIRUS DNA; VIRUS RNA; WART VIRUS VACCINE;

CANCER GRADING; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CARCINOMA IN SITU; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DOT HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE SEQUENCE; GENE TARGETING; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; IN SITU HYBRIDIZATION; MEDLINE; NONHUMAN; PAPANICOLAOU TEST; PRECANCER; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SOUTHERN BLOTTING; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 77953372612     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050802705680     Document Type: Review

References (52)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Pubitemid 29406813)
2. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79(3):328-337
3. zur-Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350
4. Selinka HC, Sotlar K, Klingel K, et al. Detection of human papillomavirus 16 transcriptional activity in cervical intraepithelial neoplasia grade III lesions and cervical carcinomas by nested reverse transcription-polymerase chain reaction and in situ hybridization. Lab Invest 1998;78:9-18 (Pubitemid 28074305)
5. Day NE. The epidemiological basis for evaluating different screening policies. IARC Sci Publ 1986;76:199-212
6. Laara E, Day NE, Hakarna M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987;1:1247-1249 (Pubitemid 17070815)
7. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-908 (Pubitemid 29191925)
8. Martin-Hirsch PL, Koliopoulos G, Paraskevaidis E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. Eur J Gynecol Oncol 2002;23:363-365 (Pubitemid 34948063)
9. Nanda K, McCrory D, Myers E, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-819 (Pubitemid 30317797)
10. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505
11. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006;195(2):349-353 (Pubitemid 44160679)
12. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265 (Pubitemid 34293391)
13. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 199;9:423-430 (Pubitemid 30184512)
14. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-518 (Pubitemid 30742935)
15. Poljak M, Marin IJ, Seme K, Vince A. Hybrid capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002;25:S89-97 (Pubitemid 35441020)
16. Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid capture 2 HPV test using polymerase chain reaction and genotyping. J Virol Methods 2006;134:252-256
17. Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papillomavirus infections. J Clin Virol 2005;32S:S43-51 (Pubitemid 40332588)
18. Poljak M, Fujs K, Seme K, et al. Retrospective and prospective evaluation of the Amplicor HPV test for the detection of 13 high risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatoven APA 2005;14:147-152 (Pubitemid 43028734)
19. Halfon P, Trepo E, Antoniotti G, et al. Prospective evaluation of the Hybrid capture 2 and AMPLICOR HPV tests for detection of 13 high risk HPV genotypes in Atypical cells of undetermned significance. J Clin Microbiol 2007;45:313-316 (Pubitemid 46272038)
20. Sandri MT, Lentati P, Benini E, et al. Comparison of Digene HCII assay and the Roche AMPLICOR Human Papillomavirus test for detection of high risk HPV genotypes in cervical samples. J Clin Microbiol 2006;44:2141-2146 (Pubitemid 43902166)
21. Takacs T, Jeney C, Kovacs L, et al. Molecular beacon-based real-time PCR method for detection of 15 high-risk and 5 low-risk HPV types. J Virol Methods 2008;149:153-162
22. Kocjan B, Seme K, Poljak M. Detection and differentiation of human papillomavirus genotypes HPV-6 and HPV-11 by FRET based real-time PCR. J Virol Methods 2008;153:245-249
23. Chan AB, Fox JD. NASBA and other transcription-based amplification methods for research and diagnostic microbiology. Rev Med Microbiol 1999;10:184-196
24. Narimatsu R, Patterson BK. High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am J Clin Pathol 2005;123:716-723 (Pubitemid 40586489)
25. ASC-US-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392 (Pubitemid 36741263)
26. Lonky NM, Felix JC, Naidu YM, et al. Wolde-Tsadik G. Triage of atypical squamous cells of undetermined significance with hybrid capture II: colposcopy and histologic human papillomavirus correlation. Obstet Gynecol 2003;101:481-489
27. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-293 (Pubitemid 38256273)
28. Safaeian M, Solomon D, Wacholder S, et al. Risk of Precancer and Follow-up Management Strategies for Women With Human Papillomavirus-Negative Atypical Squamous Cells of Undetermined Significance. Obstet Gynecol 2007;109:1325-1331 (Pubitemid 46869871)
29. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: A two-year prospective study. Am J Obstet Gynecol 2003;188(6):1401-1405 (Pubitemid 36741265)
30. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102-107 (Pubitemid 34121289)
31. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-895 (Pubitemid 41417940)
32. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2006;98:92-100 (Pubitemid 43159963)
33. Ronco G, Cuzick J, Segnan N, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43:476-480 (Pubitemid 46177594)
34. Wright TC, Massad LS, Dunton CJ, et al. Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests. J Low Genit Tract Dis 2007;11:201-222 (Pubitemid 47530909)
35. Soutter WP, de Barros Lopes A, Fletcher A, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-980 (Pubitemid 27149800)
36. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118:2048-2055
37. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(suppl 3):S78-89 (Pubitemid 44293029)
38. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testingin the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-211 (Pubitemid 38418058)
39. Zielinski GD, Bais AG, Helmerhorst TJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-553 (Pubitemid 38802827)
40. Koliopoulos G, Arbyn M, Martin-hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007;104:232-246 (Pubitemid 46054137)
41. Naucler P, Ryd W, Törnberg S, et al. Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. N Engl J Med 2007;357:1589-1597 (Pubitemid 47598401)
42. Ronco G, Giorgi-rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501
43. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527 (Pubitemid 36159887)
44. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079 (Pubitemid 41417924)
45. Berkhof J, Bulkmans NWJ, Bleeker MCG, et al. Human Papillomavirus Type-Specific 18-Month Risk of High-Grade Cervical Intraepithelial Neoplasia in Women with a Normal or Borderline/Mildly Dyskaryotic Smear. Cancer Epidemiol Biomarkers Prev 2006;15:1268-1273 (Pubitemid 44125280)
46. Varnai AD, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008;19(2):457-465 (Pubitemid 351176108)
47. Anderson S, Hansson B, Norman I, et al. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 2006;29:705-711
48. Dehn D, Torkko KC, Shroyer KR. Human Papillomavirus Testing and Molecular Markers of Cervical Dysplasia and Carcinoma Cancer. Cancer Cytopathol 2007;111:1-14
49. Molden T, Nygard JF, Kraus I, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: A 2-year follow up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-976 (Pubitemid 40504480)
50. McCaffery K, Waller J, Forrest S, et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 2004;111:1437-1443 (Pubitemid 39665037)
51. Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of Human Papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-309
52. Lie AK, Risberg B, Borge B, et al. DNA- versus RNAbased methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908-915 (Pubitemid 40824665)